PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
9.15%
Revenue growth of 9.15% vs. zero growth in Medical - Pharmaceuticals. Walter Schloss might still want to see if it can translate into profits.
5.86%
Gross profit growth exceeding 1.5x Medical - Pharmaceuticals median of 0.30%. Joel Greenblatt would check if cost advantages or brand equity drive this surge.
12.81%
EBIT growth 1.25-1.5x Medical - Pharmaceuticals median of 11.15%. Mohnish Pabrai would see if the advantage stems from superior cost management or product pricing.
12.93%
Operating income growth exceeding 1.5x Medical - Pharmaceuticals median of 4.82%. Joel Greenblatt would see if unique processes drive exceptional profitability.
-13.39%
Negative net income growth while Medical - Pharmaceuticals median is 2.42%. Seth Klarman would investigate factors dragging net income down.
-13.40%
Negative EPS growth while Medical - Pharmaceuticals median is 3.65%. Seth Klarman would explore whether share dilution or profit declines are to blame.
-13.40%
Negative diluted EPS growth while Medical - Pharmaceuticals median is 3.65%. Seth Klarman would look for the cause: weakened profitability or heavier share issuance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Dividend cuts while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would see if others maintain or grow payouts, highlighting a relative weakness.
-2.38%
Negative OCF growth while Medical - Pharmaceuticals median is -20.72%. Seth Klarman would ask if accounting or macro issues hamper the firm specifically.
-2.38%
Negative FCF growth while Medical - Pharmaceuticals median is -18.11%. Seth Klarman would see if others in the industry are still generating positive expansions in free cash.
157.75%
10Y revenue/share CAGR exceeding 1.5x Medical - Pharmaceuticals median of 42.41%. Joel Greenblatt would verify if a unique moat or brand fosters outperformance over a decade.
57.39%
5Y revenue/share growth exceeding 1.5x Medical - Pharmaceuticals median of 14.11%. Joel Greenblatt would see if the company’s moat drives rapid mid-term expansion.
27.75%
3Y revenue/share growth exceeding 1.5x Medical - Pharmaceuticals median of 15.66%. Joel Greenblatt might see a short-term competitive advantage at play.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
108.53%
Net income/share CAGR exceeding 1.5x Medical - Pharmaceuticals median of 21.53% over a decade. Joel Greenblatt might see a standout compounder of earnings.
33.23%
Net income/share CAGR of 33.23% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a modest advantage that can expand mid-term.
-13.11%
Negative 3Y CAGR while Medical - Pharmaceuticals median is 7.41%. Seth Klarman might see a pressing concern if the rest of the sector is stable or growing.
353.50%
Equity/share CAGR exceeding 1.5x Medical - Pharmaceuticals median of 50.93% over 10 years. Joel Greenblatt would see if a high ROE underlies this compounding advantage.
90.72%
5Y equity/share CAGR > 1.5x Medical - Pharmaceuticals median of 15.32%. Joel Greenblatt sees a possible ROE advantage or fewer share issuances boosting book value.
41.66%
3Y equity/share CAGR > 1.5x Medical - Pharmaceuticals median of 12.19%. Joel Greenblatt sees strong short-term returns on equity fueling net worth growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
9.07%
Receivables growth far exceeding Medical - Pharmaceuticals median. Jim Chanos suspects potential red flags in revenue quality.
3.03%
Inventory growth far above Medical - Pharmaceuticals median. Jim Chanos suspects major issues in demand forecasting or potential obsolescence risk.
3.36%
We expand assets while Medical - Pharmaceuticals is negative. Peter Lynch sees a possible advantage if expansions align with profitable markets or a recovering cycle.
2.00%
Positive BV/share change while Medical - Pharmaceuticals median is negative. Peter Lynch finds a strong advantage vs. peers failing to expand equity.
-33.66%
Debt is shrinking while Medical - Pharmaceuticals median is rising. Seth Klarman might see an advantage if growth remains possible.
No Data
No Data available this quarter, please select a different quarter.
83.99%
SG&A growth far above Medical - Pharmaceuticals median. Jim Chanos sees potential red flags in cost management or diminishing returns on spending.